Skip to main content
News > News > FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma

FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma

October 27, 2015

FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma

MILWAUKEE, WISCONSIN – This week marks another advance in the fight against skin cancer, as the U.S. Food and Drug Administration (FDA) approved a new immune-based therapy for treating melanoma lesions in the skin and lymph nodes. Amgen’s IMLYGIC (talimogene laherparepvec) commonly referred to as T-VEC, is among a new class of agents known as oncolytic virus immunotherapies. An oncolytic virus is a virus that preferentially infects and kills cancer cells. IMLYGIC is the first therapy in this class to receive FDA approval to treat melanoma….

http://www.sitcancer.org/about-sitc/newsroom/press-releases/fda-approves-imlygic-for-melanoma

 

Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.

Please read our Open Therapeutics’ company whitepaper.